Replimune Group Files 8-K on Financials
Ticker: REPL · Form: 8-K · Filed: 2024-05-16T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
Replimune dropped an 8-K on May 16th detailing their financial condition. Check it for the latest numbers.
AI Summary
Replimune Group, Inc. filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The filing details financial statements and exhibits related to the company's performance. Specific financial figures and operational updates are provided within the document.
Why It Matters
This filing provides investors with crucial updates on Replimune Group's financial health and operational performance, which can influence investment decisions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Replimune Group is subject to inherent risks associated with drug development, clinical trials, and regulatory approvals, which can significantly impact its financial condition.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- May 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38596 (identifier) — Commission File Number
- 82-2082553 (identifier) — IRS Employer Identification Number
- 500 Unicorn Park Drive Suite 303 Woburn, MA 01801 (address) — Address of principal executive offices
- ( 781 ) 222-9600 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are detailed in this 8-K filing?
The filing indicates it reports on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but specific figures are not provided in the provided text.
When was the earliest event reported in this Form 8-K?
The earliest event reported was on May 16, 2024.
What is Replimune Group, Inc.'s state of incorporation?
Replimune Group, Inc. is incorporated in Delaware.
What is the principal executive office address for Replimune Group, Inc.?
The address is 500 Unicorn Park Drive Suite 303, Woburn, MA 01801.
What is the Commission File Number for Replimune Group, Inc.?
The Commission File Number is 001-38596.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-16 08:08:47
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
Filing Documents
- tm2413978d4_8k.htm (8-K) — 26KB
- tm2413978d4_ex99-1.htm (EX-99.1) — 76KB
- 0001104659-24-062296.txt ( ) — 281KB
- repl-20240516.xsd (EX-101.SCH) — 3KB
- repl-20240516_lab.xml (EX-101.LAB) — 33KB
- repl-20240516_pre.xml (EX-101.PRE) — 22KB
- tm2413978d4_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 16, 2024, Replimune Group, Inc. (the "Company") issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2024 and certain corporate updates. A copy of the news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated May 16, 2024 104 Cover page interactive data file (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: May 16, 2024 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer